Irbesartan
Irbesartan is an approved active ingredient.
Chemical compound
Boxed warning (US label)
Fetal toxicity. When pregnancy is detected, discontinue AVAPRO as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
What it is used for
- Arterial hypertension
- Cardiovascular disease
- Diabetic nephropathy
- Chronic kidney failure
- Type 2 diabetes
AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
How it works
- Type-1 angiotensin II receptor antagonist
Common side effects
The following important adverse reactions are described elsewhere in the labeling: Hypotension in Volume or Salt-Depleted Patients Impaired Renal Function Nephropathy in type 2 diabetic patients: The most common adverse reactions which were more frequent than placebo were hyperkalemia dizziness, orthostatic…
Who should not take it
AVAPRO is contraindicated in patients who are hypersensitive to any component of this product. Do not coadminister aliskiren with AVAPRO in patients with diabetes.
Pregnancy and breastfeeding
AVAPRO can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
Interactions
- Amiloride — hyperkalemia
- Captopril — acute kidney injury, hyperkalemia, hypotension, kidney failure, syncope
- Celecoxib — increased systemic arterial blood pressure, hyperkalemia, kidney failure
- Diclofenac — kidney failure, hyperkalemia, increased systemic arterial blood pressure
- Enalapril — hypotension, acute kidney injury, kidney failure, hyperkalemia, syncope
- Ibuprofen — increased systemic arterial blood pressure, kidney failure, hyperkalemia
- Indometacin — increased systemic arterial blood pressure, hyperkalemia, kidney failure
- Ketoprofen — kidney failure, increased systemic arterial blood pressure, hyperkalemia
- Meloxicam — increased systemic arterial blood pressure, hyperkalemia, kidney failure
- Naproxen — hyperkalemia, kidney failure, increased systemic arterial blood pressure
- Perindopril — kidney failure, hyperkalemia, hypotension, acute kidney injury, syncope
- Piroxicam — increased systemic arterial blood pressure, kidney failure, hyperkalemia
- Quinapril — syncope, acute kidney injury, hyperkalemia, kidney failure, hypotension
- Ramipril — hyperkalemia, hypotension, kidney failure, syncope, acute kidney injury
- Spironolactone — hypotension, hyperkalemia
- Trimethoprim — hyperkalemia
- Lithium carbonate
Brand names
European Union
Aprovel · Ifirmasta (previously Irbesartan Krka) · Karvea
Canada
Ag-Irbesartan · Jamp Irbesartan · M-Irbesartan · Mint-Irbesartan · Nb-Irbesartan · Pendo-Irbesartan · Pms-Irbesartan · Pro-Irbesartan · Riva-Irbesartan · Sandoz Irbesartan · Spc-Irbesartan
Other trade names
Ifirmasta · Sabervel
Approval status
- US Food and Drug Administration
- prescription · since 1997
- European Medicines Agency
- authorised · since 1997
- Health Canada
- prescription · marketed
- First approval anywhere
- 1997
Codes
- ATC
- C09CA04
- RxNorm CUI
- 83818
- ChEMBL
- CHEMBL1513
- PubChem CID
- 3749
- UNII
- J0E2756Z7N
- Wikidata
- Q947266
Frequently asked questions
What is Irbesartan used for?
Irbesartan is used for: Arterial hypertension, Cardiovascular disease, Diabetic nephropathy, Chronic kidney failure, and Type 2 diabetes.
What are the brand names of Irbesartan?
Brand names of Irbesartan include Aprovel, Ifirmasta (previously Irbesartan Krka), Karvea, Ag-Irbesartan, Jamp Irbesartan, M-Irbesartan, Mint-Irbesartan, and Nb-Irbesartan.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)